# US 2014/0155319 A1 · Antimicrobial compositions and methods of use thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0155319 A1 - Document ID: US20140155319A1 - Status: Published application - Kind: A1 - Application number: 14/156,119 - Filed: 2014-01-15 - Published: 2014-06-05 - Earliest claimed: 2011-10-07 - Assignees: Morehouse School of Medicine - Applicants: Morehouse School of Medicine - Inventors: VINCENT CRAIG BOND; MICHAEL POWELL; MING BO HUANG; SYED ALI; MARTIN NEVILLE SHELTON - Web page: https://patentgrep.com/patent/US20140155319A1 ## CPC - A61K 38/162: {from virus} - A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 31/04: Antibacterial agents - C07K 7/06: having 5 to 11 amino acids - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - C12N 2740/16032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The present application discloses a method for treating microbial infection using an antimicrobial composition comprises antimicrobial peptide which contains at least one VGFPV motif. ## Claims ### Claim at position 1 1-19. (canceled) ### Claim 20 A method of treating a microbial infection, comprising: administering to a subject in need thereof an effective amount of an antimicrobial peptide comprising a first antimicrobial domain comprising two SEQ ID NO: 1 motifs, or two SEQ ID NO: 2 motifs, or one SEQ ID NO: 1 motif and two SEQ ID NO: 2 motif. ### Claim 21 (depends on 20) The method of claim 20, wherein said antimicrobial peptide has a length of 10-200 amino acids. ### Claim 22 (depends on 20) The method of claim 20, wherein said antimicrobial peptide comprises two SEQ ID NO: 1 motifs. ### Claim 23 (depends on 20) The method of claim 20, wherein said antimicrobial peptide comprises two SEQ ID NO: 2 motifs. ### Claim 24 (depends on 20) The method of claim 20, wherein said antimicrobial peptide comprises one SEQ ID NO: 1 motif and one SEQ ID NO: 2 motif. ### Claim 25 (depends on 20) The method of claim 20, wherein said antimicrobial peptide comprises SEQ ID NO: 3. ### Claim 26 (depends on 20) The method of claim 20, wherein said antimicrobial peptide comprises SEQ ID NO: 4. ### Claim 27 (depends on 20) The method of claim 20, wherein said antimicrobial peptide further comprises a second antimicrobial domain, wherein said second antimicrobial domain is different from said first antimicrobial domain. ### Claim 28 (depends on 20) The method of claim 20, wherein said antimicrobial peptide further comprises a cell penetrating peptide (CPP) domain. ### Claim 29 (depends on 20) The method of claim 20, wherein said antimicrobial peptide further comprises a targeting domain. ### Claim 30 (depends on 20) The method of claim 20, wherein said antimicrobial peptide is a PEGylated peptide. ### Claim 31 (depends on 20) The method of claim 20, wherein said microbial infection is a bacterial infection. ### Claim 32 (depends on 31) The method of claim 31, wherein said bacterial infection is an infection of gram positive bacteria. ### Claim 33 (depends on 31) The method of claim 31, wherein said bacterial infection is an infection of gram negative bacteria. ### Claim 34 (depends on 31) The method of claim 31, wherein said bacterial infection is an infection of a bacterial species selected from the group consisting of Staphylococcus species, Enterococcus species, Mycobacterium species, Haemophilus species, Pseudomonas species, Salmonella species, Shigella species, Brucella species, Neisseria species, Escherichia coli, Vibrio cholerae, Helicobacter pylori, Chlamydia trachomatis, Clostridium difficile, Cryptococcus neoformans, Moraxella catarrhalis, Campylobacter species, Corynebacterium species, Streptococcus species, Listeria monocytogenes, Nocardia asteroides, Bacteroides species, Actinomycetes species, Treponema pallidum, Leptospirosa species, Klebsiella pneumoniae; Proteus species, Serratia species, Acinetobacter, Yersinia species, Francisella tularensis, Enterobacter species, Bacteriodes species, Legionella species and Borrelia burgdorferi. ### Claim 35 A method of treating a microbial infection, comprising: administering to a subject in need of such treatment an effective amount of an expression vector capable of expressing an antimicrobial peptide, wherein said antimicrobial peptide comprises a first antimicrobial domain comprising two SEQ ID NO: 1 motifs, or two SEQ ID NO: 2 motifs, or one SEQ ID NO: 1 motif and two SEQ ID NO: 2 motif. ### Claim 36 (depends on 35) The method of claim 35, wherein said expression vector is a plasmid expression vector. ### Claim 37 (depends on 35) The method of claim 35, wherein said expression vector is a viral expression vector. ### Claim 38 (depends on 35) The method of claim 35, wherein said expression vector is a bacteria phage displaying said antimicrobial peptide on its surface ### Claim 39 A pharmaceutical composition for treating microbial infection, comprising: (1) an antimicrobial peptide comprising an antimicrobial domain comprising two SEQ ID NO: 1 motifs, or two SEQ ID NO: 2 motifs, or one SEQ ID NO: 1 motif and two SEQ ID NO: 2 motif; and a cell penetrating peptide (CPP) domain and/or a targeting domain; and (2) a pharmaceutically acceptable carrier.